Protagenic Therapeutics Terminates CFO Amidst Going Concern Warning

summarizeSummary

Protagenic Therapeutics announced the termination of its Chief Financial Officer, Alexander Arrow, effective April 30, 2026, following recent disclosures of a 'going concern' warning and material weaknesses.

check_boxKey Events

• CFO Termination Announced

  Alexander Arrow, MD, the Chief Financial Officer, was notified on March 31, 2026, that his employment will be terminated effective April 30, 2026.

• Context of Financial Distress

  This termination occurs shortly after the company disclosed a 'going concern' warning and material weaknesses in internal controls in its last 10-Q filing on March 9, 2026.

auto_awesomeAnalysis

The termination of the Chief Financial Officer at Protagenic Therapeutics is a significant negative development, especially given the company's recent disclosure of a 'going concern' warning and material weaknesses in internal controls. The CFO is typically responsible for financial oversight and reporting, making their departure during a period of financial instability particularly concerning. Investors should monitor for further updates regarding financial leadership and the company's ability to address its 'going concern' issues.